
Phase III trial for the ABNCoV2 COVID-19 vaccine to start inclusion of Danish subjects

Hørsholm, Denmark, October 7, 2022 – ExpreS²ion Biotech Holding AB's affiliate ExpreS²ion Biotechnologies ApS ("ExpreS²ion") announces that Bavarian Nordic's ongoing Phase III clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 booster vaccine, which started to include subjects in the United States in September, will also start to include subjects in Denmark in October. The Danish part of the study will be conducted at hospitals on Zealand, Jutland and Funen.

Danish subjects included in the study will assist in the evaluation of the ABNCoV2 vaccine compared to a licensed mRNA-based vaccine, and they will receive one of these vaccines.

If the Phase III clinical trial is successful, Denmark will be one of the first countries to receive doses of the ABNCoV2 vaccine after regulatory approval. This is due to an agreement between the Danish state and Bavarian Nordic that was signed in 2021, where the Danish state agreed to co-finance the final part of the development program in exchange for doses of the vaccine once it is approved.

People who would like to participate in this Phase III trial can contact Bavarian Nordic via telephone on +45 24 67 34 85 or via email on info@bavarian-nordic.com.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmq.se

For further information about ExpreS²ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS²ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS²ion owns 34%. For additional information, please visit www.expres2ionbio.com.